- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02497534
Biomarkers in Friedreich's Ataxia
August 29, 2023 updated by: University of Florida
The purpose of this project is to characterize measures of cardiac performance and neuromuscular physiology in FA patients using novel techniques, including echocardiography and magnetic resonance imaging (MRI), metabolic exercise testing, and neurophysiological outcomes.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Friedreich's ataxia (FA) is an autosomal recessive disease caused by a mutation in the frataxin gene (FXN).
Although rare, FA is the most common form of hereditary ataxia, affecting 1 in every 50,000 people in the United States.
Currently, palliative therapies are the only treatment for FA patients.
However, current gene therapy efforts in other neuromuscular diseases have positioned the investigator's research program to extend these discoveries and techniques to FA.
As new therapies become available for clinical application, it is crucial to identify non-invasive outcomes measures of cardiac and neuromuscular performance with adequate sensitivity to detect the impact of treatments.
Study Type
Observational
Enrollment (Estimated)
203
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mackenzi Coker, M.S.CCC-SLP
- Phone Number: 352-294-8754
- Email: mcoker@peds.ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- University of Florida
-
Contact:
- Mackenzi Coker, MS, CCC-SLP
- Phone Number: 352-273-8754
- Email: mcoker@ufl.edu
-
Sub-Investigator:
- Sub Subramony, MD
-
Principal Investigator:
- Manuela Corti, PT, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 68 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Subjects with Friedreich's ataxia, healthy control subjects, and carriers of Friedreich's ataxia
Description
Inclusion Criteria:
- Genetic diagnosis of Friedreich's ataxia by DNA sequencing, mutational analysis or protein assay OR be a healthy subject with no evidence of a neuromuscular disorder
- Between the ages of 8 and 70 (inclusive)
- Are able to tolerate metabolic exercise testing
- Are stable on cardiac medication regimen for 3 months prior to screening
Exclusion Criteria:
- Presence of unstable heart disease
- Receipt of cardiac transplant
- Any concurrent medical condition which, in the opinion of the investigators, would make the subject unsuitable for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
Affected with Friedreich's ataxia
Friedreich's ataxia patients aged 8 to 70 (inclusive).
Assessments will include collection of genetic mutation reports, cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing with a recombinant bike and/or hand ergometer, pulmonary function testing, and gait analysis.
Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
|
Healthy controls
Health controls aged 8 to 70 (inclusive).
Assessments will include cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing, hand ergometer for exercise testing, pulmonary function testing, gait analysis, and an optional blood draw.
|
Carriers of Friedreich's ataxia
An obligate carrier aged 18 to 70 (inclusive) of the abnormal Friedreich's ataxia gene by being a parent of a child with Friedreich's ataxia.
No assessments are to be conducted.
Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac MRI
Time Frame: Baseline and Follow-Up Visits
|
Cardiac MRI will be used to characterize cardiac morphology and function.
|
Baseline and Follow-Up Visits
|
Echocardiogram
Time Frame: Baseline and Follow-Up Visits
|
Echocardiogram will be used to characterize cardiac morphology and function.
|
Baseline and Follow-Up Visits
|
Friedreich's Ataxia Rating Scale (FARS)
Time Frame: Baseline and Follow-Up Visits
|
FARS scores describe specific neurological impairments in FA.
|
Baseline and Follow-Up Visits
|
Metabolic exercise testing
Time Frame: Baseline and Follow-Up Visits
|
Metabolic exercise testing will be performed on either a recumbent bike or hand ergometer and will measure the maximal amount of exercise the subject is able to perform.
|
Baseline and Follow-Up Visits
|
Scale for the Assessment and Rating of Ataxia (SARA)
Time Frame: Baseline and Follow-Up Visits
|
Clinical scale assessing impairment levels in cerebellar ataxia
|
Baseline and Follow-Up Visits
|
Muscle Biopsy
Time Frame: Baseline
|
The muscle sample will be used to evaluate Frataxin quantification
|
Baseline
|
Skin Biopsy
Time Frame: Baseline
|
Analyses to peripheral tissue used to find out how Friedreich's Ataxia develops.
|
Baseline
|
9-Hole-Peg Test
Time Frame: Baseline and Follow-Up Visits
|
Assesses upper extremity function and motor coordination.
|
Baseline and Follow-Up Visits
|
Pulmonary Function Testing
Time Frame: Baseline and Follow-Up Visits
|
Breathing tests to assess lung strength and function.
|
Baseline and Follow-Up Visits
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Manuela Corti, PT, PhD, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Estimated)
June 3, 2030
Study Completion (Estimated)
June 3, 2030
Study Registration Dates
First Submitted
July 7, 2015
First Submitted That Met QC Criteria
July 9, 2015
First Posted (Estimated)
July 14, 2015
Study Record Updates
Last Update Posted (Actual)
September 1, 2023
Last Update Submitted That Met QC Criteria
August 29, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Dyskinesias
- Spinal Cord Diseases
- Heredodegenerative Disorders, Nervous System
- Mitochondrial Diseases
- Cerebellar Diseases
- Spinocerebellar Degenerations
- Ataxia
- Cerebellar Ataxia
- Friedreich Ataxia
Other Study ID Numbers
- IRB201500369-N
- UL1TR000064 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Friedreich's Ataxia
-
University of ChicagoPfizer; Biogen; APDM Wearable TechnologiesActive, not recruitingSpinocerebellar Ataxia Type 3 | Friedreich Ataxia | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6United States
-
University of South FloridaCompletedFriedreich's Ataxia | Spinocerebellar Ataxia - All Sub-typesUnited States
-
Santhera PharmaceuticalsCompletedFreidreich's AtaxiaGermany, Netherlands, France, Austria, Belgium
-
Institut National de la Santé Et de la Recherche...Not yet recruiting
-
PTC TherapeuticsEnrolling by invitationFriedreich AtaxiaUnited States, Australia, Brazil, Canada, France, Germany, Italy, New Zealand, Spain
-
PTC TherapeuticsActive, not recruitingFriedreich AtaxiaUnited States
-
PTC TherapeuticsCompletedFriedreich AtaxiaUnited States, Australia, Brazil, Canada, France, Germany, Italy, New Zealand, Spain
-
Children's Hospital of PhiladelphiaFriedreich's Ataxia Research Alliance; Stealth BioTherapeutics Inc.Active, not recruitingFriedreich AtaxiaUnited States
-
Metro International Biotech, LLCChildren's Hospital of PhiladelphiaCompleted
-
Santhera PharmaceuticalsCompletedFriedreich's AtaxiaUnited States